Comparison · NCT04008069-d3aa683a
Double-Blind Sarilumab (Post-randomization) vs Double-Blind Placebo (Post-randomization): Number of Participants Without Sarcoidosis Flare (Flare-Free Survival)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Double-Blind Sarilumab (Post-randomization) vs Double-Blind Placebo (Post-randomization): Number of Participants Without Sarcoidosis Flare (Flare-Free Survival). Trial comparisons, record NCT04008069-d3aa683a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04008069-d3aa683a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.342 | 1 | wilson | |
| Risk in group 2 | 0.875 | 0.529 | 0.978 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.541 | 0.471 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.88 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Double-Blind Sarilumab (Post-randomization) than on Double-Blind Placebo (Post-randomization) | 8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Double-Blind Sarilumab (Post-randomization) | After completing the open-label period, participants are randomized to receive sarilumab every two weeks for 12 weeks. | 2 | 2 | OG000 |
| Group 2 | Double-Blind Placebo (Post-randomization) | After completing the open-label period, participants are randomized receive placebo every two weeks for 12 weeks. | 7 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Without Sarcoidosis Flare (Flare-Free Survival)
- Description
The primary outcome was flare-free survival of sarilumab-treated patients compared to placebo-treated controls. Patients will be considered to have flared if they receive rescue medication including increased glucocorticoids, or if they discontinue the study treatment in order to start a different therapy.
- Time frame
- Week 16 to Week 28
- Population
- Assessed in participants in the randomized-withdrawal period
Source ClinicalTrials.gov
Trial
- Title
- Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
- NCT number
- NCT04008069
- Phases
- PHASE2
- Conditions
- Sarcoidosis
- Interventions
- Sarilumab, Placebo
- Lead sponsor
- Stanford University
- Results first posted
- 2023-10-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04008069?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04008069-d3aa683a